ETON NASDAQ
Eton Pharmaceuticals, Inc.
1W: +16.8%
1M: +48.2%
3M: +95.2%
YTD: +115.2%
1Y: +78.6%
3Y: +872.2%
5Y: +324.2%
$32.59
-2.41 (-6.89%)
Weekly Expected Move ±11.7%
$23
$27
$30
$34
$37
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (40)
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
Eton (ETON) Q1 2026 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
Full Transcript: Eton Pharmaceuticals Q1 2026 Earnings Call
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Brokerages
Eton Pharma drops after CFO succession plan
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Recommendation of “Moderate Buy” by Brokerages
Eton Pharmaceuticals (NASDAQ:ETON) Hits New 52-Week High After Analyst Upgrade
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?
Recent Price Trend in Eton Pharmaceuticals (ETON) is Your Friend, Here's Why
Eton Pharmaceuticals (NASDAQ:ETON) Sees Strong Trading Volume on Analyst Upgrade
Does Eton Pharmaceuticals (ETON) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?
Eton Pharma (ETON) Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates
Eton Pharmaceuticals Non-GAAP EPS of $0.19 misses by $0.01, revenue of $21.3M beats by $0.72M
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Here are the major earnings after the close Thursday
Earnings Scheduled For March 19, 2026
Eton Pharmaceuticals Q4 2025 Earnings Preview
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Rating of “Hold” by Brokerages
Q2 EPS Estimate for Eton Pharmaceuticals Lifted by Analyst
Research Analysts Offer Predictions for ETON Q1 Earnings
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
Eton wins FDA nod for rare disorder therapy Desmoda
US FDA approves Eton Pharma's hormonal disorder drug
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
Catalyst Watch: Nvidia blockbuster, JPMorgan event, and reactions to the tariff reset
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
Eton Pharmaceuticals: An Undervalued Small Cap With High Growth
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th